medigraphic.com
ISSN 2448-8909 (Print)

2011, Number 3

<< Back Next >>

Med Crit 2011; 25 (3)

Dipiridamol en preeclampsia

Briones GJC, Díaz de LPMA, Briones VCG

Language: Spanish
References: 36
Page: 150-156
PDF size: 326.92 Kb.


ABSTRACT

Introduction: Pre-eclampsia is responsible for maternal-fetal deaths and neonatal primary prevention is the only contraception, pathophysiology involves penetration with deficient trophoblast invasion of spiral arteries, uterine-placental vessels with high strength, conditioning hypoxia, ischemia, platelet activation and neutrophils, with increased permeability and vascular spasm. Dipyridamole is a potent inhibitor of phosphodiesterase responsible for cGMP hydrolysis, so it is likely to act enhancing the effects of nitric oxide (NO) a potent vasodilator and inhibitor of platelet aggregation.
Objective: Intended to demonstrate the clinical effects observed with dipyridamole in a woman with two perinatal losses, recurrent preeclampsia and antiphospholipid syndrome.
Site: Research Unit Maternal and Perinatal Hospital-ISEM.
Case report: 26 years Gesta III, I, C-section I (stillbirths), continued throughout pregnancy, biochemical tests, hematological, ultrasound and thoracic bioimpedance and quarterly income.
Results: Interrupted abdominal pregnancy at 37 weeks, female newborn of 1,720 g, Apgar 8-9, binomial evolved without complications.
Discussion: Dipyridamole in preeclampsia is a contribution of a Díaz de León and Briones, improving perfusion to multiple organ level effect on vascular resistance.


REFERENCES

  1. Gamboa A, Abraham R, et al. Role of adenosine and nitric oxide on the mechanisms of action of dypiridamole. Stroke 2005;36;2170-2175.

  2. Zamorski MA, Green LA. Preeclampsia and the hypertensive disorders of pregnancy. Clin Fam Prac 2001;3:2.

  3. Seventh report of the joint committee o prevention, detection, evaluation and treatment of high blood pressure. Hypertension 2003;42:1206-1252.

  4. The perinatal antiplatelet review of international studies (PARIS). Antiplatelet agents for prevention of preeclampsia and it’s consequences an systematic review and individual patient data meta-analysis. BMC Pregnancy and childbirth 2005;5:7.

  5. Weyrich AS, Denis MM, Kuhlmann-Eyre JR, Specer ED et al. Dipyridamole selectively inhibits inflammatory gene expression in monocyte-platelet aggregates. Circulation 2005;111:633-642.

  6. Coomarasamy A, Honest H, Papaioannou S, Gee H, Khan KS. Aspirin for prevention of preeclampsia in women with historical risk factors: a systematic review. Obstet Gynecol 2003;101:1319-1332.

  7. Dekker G, Sibai B. Primary, secondary and tertiary prevention of pre-eclampsia. Lancet 2001;357:209-15.

  8. Robillard PY, Hulsey TC, Perianin J, Janky E, Miri EH, Papiernik E. Association of pregnancy-induced hypertension with duration of sexual cohabitation before conception. Lancet 1994;344:973-75.

  9. Lie RT, Rasmussen S, Brunborg H, Gjessing HK, Lie-Nielsen E, Irgens LM. Fetal and maternal contributions to risk of preeclampsia. BMJ 1998;316:1343-47.

  10. Conde-Agudelo A, Belizan JM. Risk factors for pre-eclampsia in a large cohort of Latin American and Caribbean women. Br J Obstet Gynaecol 2000;107:75-83.

  11. Bosio PM, McKenna PJ, Conroy R, O’Herlihy. Maternal central hemodynamics in hypertensive disorders of pregnancy. Obstet Gynecol 1999;94:978-84.

  12. Dekker GA, Sibai BM. Etiology and pathogenesis of preeclampsia: current concepts. Am J Obstet Gynecol 1998;179:1359-75.

  13. Mortalidad materna y perinatal. Acciones para su reducción. Cifras y hechos, 1989-1994, México: Secretaría de Salud 1995.

  14. Olsen S, Secher NJ, Tabor A, Weber T, Walker JJ, Gluud C. Randomized clinical trials of fish oil supplementation in high risk pregnancies. Br J Obstet Gynaecol 2000;107:382-95.

  15. Duley L, Henderson-Smart D, Knight M, King J. Antiplatelet drugs for prevention of preeclampsia and it’s consequences: systematic review. BMJ 2001;322:329-33.

  16. Knight M, Duley L, Henderson-Smart DJ, King JF. Antiplatelet agents and pre-eclampsia (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford, Uptade Software, 2000.

  17. Marti JJ, Hermann U. Immunogestosis: a new etiologic concept of “essential” EPH gestosis, with special consideration of the primigravid patient. Am J Obstet Gynecol 1977;128:489-93.

  18. Carbillon L, Uzan M, Uzan S. Pregnancy, vascular tone, and maternal hemodynamics: a crucial adaptation. Obstet Gynecol Surv 2000;55:574-81. Principio del formulario.

  19. Ronces VR, Díaz de León PM, Torres ZM. La coagulación intravascular en la patología renal. Med Klin 1972;129:36-39.

  20. Díaz de León PM, et al. Necrólisis epidérmica tóxica. Avance terapéutico. Arch Invest Med 1973;2:153-158.

  21. Díaz de León PM, Exaire EME, Ronces VR, Pizuto CHI. Glomerulonefritis rápidamente progresiva tratada con anticoagulantes y antitrombóticos. Boletín Med IMSS 1975;2:49-54

  22. Díaz de León PM, Espinosa MLM, López Llera MM, Rubio LG. Coagulación intravascular e insuficiencia renal aguda en el choque séptico. Tratamiento con antitrombóticos. Rev Mex Anest Ter Int 1975;6:583-590.

  23. Díaz de León PM, Kabli AA, Espinosa MLM, Vázquez MS. Evaluación del uso profiláctico del dipiridamol en obstetricia. Ginec Obstet Mex 1977;253:309-314.

  24. Díaz de León PM, Espinoza MLM, Martines GM, Conde MI. Antitrombóticos en el choque séptico en obstetricia. Rev Med Anest 1978;4:259-264.

  25. Díaz de León PM, López Llera MM, Espinosa MLM, Rubio LG. Medicación antitrombótica en el tratamiento de insuficienciarenal aguda en la toxemia del embarazo. Arch Invest Med Mex 1980;11:9-19.

  26. Díaz de León PM, Vargas SLB, Espinosa MML, Martínez GM. Insuficiencia renal aguda, anemia hemolítica y trombocitopenia en toxemia del embarazo. Nefrología Mexicana 1981;5:13.

  27. Espinosa MML, Díaz de León PM, Yañez MI, Neninger CHJH, Colmenares MI. Microangiopatía trombótica y hemólisis intravascular en la toxemia. Rev Med IMSS (Méx.) 1982;20:35.

  28. Weinstein L. Syndrome of hemolysis, elevated liver enzymes and low platelet count: A severe consequence of hypertension in pregnancy. Am J Obstet Gynecol 1982;142:159.

  29. Briones GJC, Díaz de León PM, Gómez BTE, Ávila EF, Briones VCG, Urrutia TF. Protocolo de manejo en la preeclampsia

  30. Briones GJC, Gómez BTE, Ávila EF, Díaz de León PM. Experiencia TOLUCA en preeclampsia-eclampsia. Cir Ciruj 2005;73:101-105.

  31. Briones GJC, Díaz de León PM, Irigoyen CL, Martínez BL, Briones VCG, Urrutia TF. Anticuerpos anticardiolipina en la preeclampsia/eclampsia. Rev Asoc Mex Med Crit y Ter Int 1997;11(6):194-196.

  32. Briones GJC, Díaz de León PM, Barrios PE, Salazar EJD. Anticuerpo antifosfolípido IgM en preeclampsia-eclampsia. Cir Ciruj 2003;71:449-454.

  33. Meneses CJ, Díaz de León PM, Moreno SAA, González DJI, Amezola CMA, Jiménez AEP, García CG, Salinas EA, Briones GJC. Medición de valores hemodinámicos en embarazo normoevolutivo y puerperio fisiológico inmediato por bioimpedancia torácica. Rev Asoc Mex Med Crit y Ter Int 2007;21(3):149-153.

  34. Meneses CJ, Moreno SAA, González DJI, Díaz de León PM, Rodríguez RM, Castorena AR, García CG, Mendoza AMA, Briones GJC. Medición hemodinámica en preeclampsia severa. Rev Asoc Mex Med Crit y Ter Int 2008;22(1):10-14.




2020     |     www.medigraphic.com